<p>Low microRNA-622 expression predicts poor prognosis and is associated with ZEB2 in glioma</p>

Abstract

BackgroundMicroRNAs have been recently reported to play an important role in tumorigenesis and progression in several forms of tumors. Previous studies have shown that microRNA-622 (miR-622) was associated with glioma proliferation and invasion. However, the clinical significance of miR-622 in glioma has not been elucidated. The aim of our study was to investigate the clinical values of miR-622, as well as investigate the potential molecular mechanisms in glioma.Materials and methodsqRT-PCR and Western blot analysis were used to analyze the expression of miR-622 and ZEB2, respectively. Kaplan–Meier analysis and Cox’s proportional hazards model were used in survival analysis. MTT assay, wound healing assay, transwell assay and flow cytometry analysis were carried out to detect the impact of miR-622 on glioma cell proliferation, migration, invasion and apoptosis.ResultsOur result indicated that miR-622 expression was greatly decreased in glioma tissues and cell lines and the downregulation of miR-622 was significantly associated with the advanced pathological grade and low Karnofsky performance score of glioma. In addition, Kaplan–Meier curves with log-rank analysis revealed a close correlation between downregulation of miR-622 expression and low overall survival rate in glioma patients. Furthermore, Cox regression analysis demonstrated that downregulated miR-622 could be considered as an independent poor prognostic indicator in glioma patients. Finally, our findings demonstrated that miR-622 overexpression remarkably suppressed glioma cell proliferation, migration and invasion, while facilitated apoptosis by suppressing ZEB2 in vitro.ConclusionOur study suggested that miR-622 may be identified as a valuable prognostic biomarker and a promising therapeutic target for glioma patients.

ZEB2 facilitates peritoneal metastasis by regulating the invasiveness and tumorigenesis of cancer stem-like cells in high-grade serous ovarian cancers

“…From the perspective of translational application, ZEB2 has been reported as an adverse prognostic marker in some tumours, such as breast cancer [ 38 ], bladder carcinoma [ 39 ] and glioma [ 40 ]. We thus retrospectively analysed 98 HGSOC patients to clarify the relationship between ZEB expression and clinical outcome.…”

MicroRNA-136-3p inhibits glioma tumorigenesis in vitro and in vivo by targeting KLF7

“…Nowadays, increasing studies have proved that a series of miRNAs are involved in progression of multiple styles of tumors [7][8][9][10][11][12][13]. For instance, miR-662 [6], miR-532-5p [14], miR-199a [15], miR-940 [24], miR-200b [17], miR-34a [18], miR-130b [19], and miR-148a [20] all play an essential role in gliomas. Herein, we investigated the role of miR-136-3p and its target gene KLF7 in glioma development.…”

“…Although multiple therapies, including surgery, radiotherapy, and chemotherapy, have been developed for therapeutic treatment of glioma, the prognosis remains poor and the survival rate of 5 years no more than 10% due to its heterogeneous characteristics [ 1 , 3 ]. Up to now, few biological risk factors and effective therapeutic targets have been identified to better glioma treatment [ 4 – 6 ]. Thus, it is vital to find novel prognostic and therapeutic targets for glioma patients.…”

“…in tumorigenesis including cell proliferation, migration, apoptosis, and angiogenesis [10][11][12][13]. For example, miR-622 levels predict poor prognosis and it exhibits functions by targeting zinc finger E-box binding homeobox 2 (ZEB2) in glioma [6]. MiR-532-5p inhibits glioma cell proliferation by targeting colony-stimulating factor 1 (CSF1) [14].…”

MiR‐622 acts as a tumor suppressor to induce cell apoptosis and inhibit metastasis in human prostate cancer

“…Increasing evidence suggests that down‐regulation of miR‐622 has been indicated in diverse lines of studies in human malignancies, including pancreatic cancer, renal cell carcinoma, gastric cancer, CRC and glioma (Guo et al., 2011; Li et al., 2018; Orlandella et al., 2020; Song et al., 2019; Wang et al., 2017). In this regard, in breast cancer cells, miR‐622 affects tumour cells' motility phenotype by suppressing NUAK1 kinase (Orlandella et al., 2020).…”